HIMS Stock: New Testosterone Push Builds as GLP-1 Market Crowds | Meta Platforms Stock: Key Updates and Analyst Ratings for Q1 2026 | NFL Teams Stocking Up on First-Round Talent in 2026 | Morgan Stanley Exceeds Expectations in Q1 2026 | Wegovy Maker Challenges Weight-Loss Drug Copycats Amidst Telehealth Boom | Hims & Hers Announces $49 Wegovy Copy, Novo Nordisk and Eli Lilly Tumble | Meta Platforms Stock: Is the Dip a Buying Opportunity? | Jo Koy Films Stockton and Hershey Shows for Netflix Special | HIMS Stock: New Testosterone Push Builds as GLP-1 Market Crowds | Meta Platforms Stock: Key Updates and Analyst Ratings for Q1 2026 | NFL Teams Stocking Up on First-Round Talent in 2026 | Morgan Stanley Exceeds Expectations in Q1 2026 | Wegovy Maker Challenges Weight-Loss Drug Copycats Amidst Telehealth Boom | Hims & Hers Announces $49 Wegovy Copy, Novo Nordisk and Eli Lilly Tumble | Meta Platforms Stock: Is the Dip a Buying Opportunity? | Jo Koy Films Stockton and Hershey Shows for Netflix Special
Hims & Hers Health, Inc. (HIMS) is expanding its focus on testosterone therapies as competition intensifies in the GLP-1 weight-loss market. The company's stock experienced a boost following the announcement of its new Testosterone Rx+ offe...
HIMS Stock Options Traders Are Pricing In a Huge Price Swing after Earnings
Meta Platforms (META) has seen significant activity in Q1 2026, with institutional investors adjusting their positions, analysts updating their ratings, and insiders engaging in notable trading. This article provides a concise recap of thes...
Timber Creek Capital Management LLC Acquires 2,433 Shares of Meta Platforms, Inc. $META
The 2026 NFL Draft is shaping up to be an exciting event, with several teams holding multiple first-round picks. These teams are strategically positioned to add significant talent to their rosters, while others have traded away their top se...
Giants join Dolphins, Jets, Cowboys, Chiefs, Browns as teams with two first-round picks
Morgan Stanley (MS) has announced its Q1 2026 earnings, surpassing analyst expectations due to a significant boost in trading revenue. The firm reported earnings of $3.43 per share against an LSEG estimate of $3, with revenue reaching $20.5...
Morgan Stanley tops estimates as trading revenue exceeds expectations by $1 billion
The market for weight-loss drugs is heating up as Novo Nordisk, the maker of Wegovy, takes legal action against telehealth companies like Hims & Hers for offering compounded versions of its popular medication. This comes as analysts see a p...
GLP-1 wars: Wegovy maker challenges knock-off weight loss drug companies
Online telehealth company Hims & Hers is set to launch a copy of the Wegovy pill for $49, significantly undercutting Novo Nordisk’s $149 branded version. This announcement has sent shockwaves through the pharmaceutical market, impacting the...
Novo Shares Fall As Hims & Hers Offers $49 Wegovy Copycat
Meta Platforms (META) has seen its stock price decline recently, erasing post-earnings gains. This article examines the factors contributing to this dip and assesses whether it presents a buying opportunity for investors.
Down About 10% in Less Than a Week, Is Meta Platforms Stock a Buy?
Comedian Jo Koy is taping shows in Stockton, California, and Hershey, Pennsylvania for an upcoming Netflix comedy special, offering fans a chance to be part of comedy history. The shows draw inspiration from his Filipino-American upbringing...
‘Rare chance to be part of comedy history.’ Jo Koy to film Stockton shows for Netflix
This article examines the investment potential of Hims & Hers Health, Inc. (HIMS) and Okta, Inc. (OKTA), analyzing their growth strategies, recent performance, and key market factors influencing their stock trends. Both companies represent...
Hims & Hers Health (HIMS) is venturing into GLP-1 microdosing treatments, sparking interest and debate in the telehealth and weight management sectors. This move coincides with the company's upcoming Q3 earnings report, adding to the market...
Hims & Hers Health (HIMS): Exploring Valuation as Q3 Earnings and GLP-1 Launch Boost Market Activity
Hims & Hers Health, Inc. (HIMS) recently experienced a stock decline that surpassed the losses seen in the broader market. This article breaks down the factors influencing this downturn and what investors should consider.
Here's Why Hims & Hers Health, Inc. (HIMS) Fell More Than Broader Market
Shares of Hims & Hers Health (HIMS) experienced a surge following the announcement of new perimenopause and menopause treatment options. This move signals a significant expansion into women's health, offering personalized treatment plans an...
Hers Launches Menopause and Perimenopause Specialty, Taking the Next Step Toward $1B of Hers Revenue in 2026
Morgan Stanley (MS) announced a substantial earnings beat for the third quarter of 2025, surpassing expectations by the largest margin in nearly five years. The surge was fueled by a strong resurgence in investment banking activity and robu...
Morgan Stanley posts massive third-quarter earnings beat
Hims & Hers Health (HIMS) has experienced significant stock fluctuations recently. This article examines the factors driving these movements, including insider trading activity, hedge fund positions, analyst ratings, and regulatory challeng...
$HIMS stock is down 8% today. Here's what we see in our data.
Hims & Hers Health, Inc. (HIMS) has seen significant activity in institutional investment and insider trading, alongside mixed analyst ratings. This article provides a recap of these developments, offering insights for investors monitoring...
Dakota Wealth Management Takes Position in Hims & Hers Health, Inc. $HIMS
An analysis of Hims & Hers Health (HIMS) stock, examining its recent market performance, future growth prospects, and overall investment appeal. The stock's movements are contextualized within broader market trends and industry benchmarks.
Hims & Hers Health, Inc. (HIMS) Stock Sinks As Market Gains: Here's Why
Recent reports highlight increased investment activity and analyst optimism surrounding Meta Platforms, Inc. (NASDAQ:META). Several institutional investors have adjusted their positions, and analysts have raised price targets, reflecting co...
Vestmark Advisory Solutions Inc. Acquires 11,213 Shares of Meta Platforms, Inc. (NASDAQ:META)
Recent market activity has been marked by mixed results. Hims & Hers Health saw its stock decline after a revenue miss, while the S&P 500 rebounded strongly. ThredUp experienced a surge following a Q2 earnings beat. Here's a quick recap com...
This week's market activity is influenced by Hims & Hers' upcoming earnings report, Nio's struggles in the Chinese EV market, and American Eagle's controversial ad campaign. Each of these events is driving significant attention and market m...
All eyes are on Hims’ weight-loss biz ahead of Monday earnings
Hims & Hers Health, Inc. (HIMS) has garnered significant investor interest due to its impressive growth and market performance. This article examines the factors driving HIMS's stock trend and provides insights into its potential future.
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know